NCT02573636 The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy
| NCT ID | NCT02573636 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sir Mortimer B. Davis - Jewish General Hospital |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 208 participants |
| Start Date | 2016-03 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 208 participants in total. It began in 2016-03 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after biochemical failure.
Eligibility Criteria
Inclusion Criteria: * T3a + * PSA \> 20 * Gleason 8 or higher * Karnofsky performance status ≥ 70. * Signed study-specific informed consent Exclusion Criteria: \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02573636 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02573636 currently recruiting?
Yes, NCT02573636 is actively recruiting participants. Contact the research team at yanqi.feng.ccomtl@ssss.gouv.qc.ca for enrollment information.
Where is the NCT02573636 trial being conducted?
This trial is being conducted at Chicoutimi, Canada, Greenfield Park, Canada, Laval, Canada, Montreal, Canada and 5 additional locations.
Who is sponsoring the NCT02573636 clinical trial?
NCT02573636 is sponsored by Sir Mortimer B. Davis - Jewish General Hospital. The trial plans to enroll 208 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.